{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:57:21Z","timestamp":1776171441758,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The beneficial effects of renin angiotensin aldosterone system (RAAS) blockade on residual renal function (RRF) in patients who have just initiated hemodialysis (HD) have been inconclusive. In this study, 935 patients with incident HD from a nationwide prospective observational cohort in Korea were included for analysis. The primary outcome showed that RRF as demonstrated by urine volume changes over 0, 3, and 12 months differed between the RAAS blockade and control groups. Mixed-effects linear regression was used to compare RRF between the groups. Patients in the RAAS group had a greater proportion of higher urine volume at study enrollment compared to the control group, but there was no difference in baseline characteristics, heart function, and dialysis-related indices. After adjusting for confounding factors, the RAAS group did not provide a significant benefit to RRF in a mixed-effects linear regression (p\u2009=\u20090.51). Male gender, high Charlson comorbidity index, diuretic use, and high weekly ultrafiltration volume were associated with faster decline in RRF. The RAAS group failed to provide a protective effect for the development of anuria 1 year after initiating dialysis based on the multivariate logistic regression (OR 0.73 95% CI 0.25\u20132.13, p\u2009=\u20090.57). In Korean patients with incident HD, RAAS blockade did not provide a protective effect for RRF after 1 year. Further research is needed to clarify the optimal treatment for preserving RRF in HD patients.<\/jats:p>","DOI":"10.1038\/s41598-019-54572-6","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:37:14Z","timestamp":1575286634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Renin Angiotensin Aldosterone System Blockades Does Not Protect Residual Renal Function in Patients with Hemodialysis at 1 Year After Dialysis Initiation: A Prospective Observational Cohort Study"],"prefix":"10.1038","volume":"9","author":[{"given":"Kyung Don","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Tammy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soie","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-635X","authenticated-orcid":false,"given":"Jeonghwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Kyu","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Woo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Lim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yon Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-1260","authenticated-orcid":false,"given":"Jung Pyo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"54572_CR1","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1681\/ASN.2015101142","volume":"27","author":"Y Obi","year":"2016","unstructured":"Obi, Y. et al. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. Journal of the American Society of Nephrology 27, 3758\u20133768 (2016).","journal-title":"Journal of the American Society of Nephrology"},{"key":"54572_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/01.ASN.0000117976.29592.93","volume":"15","author":"F Termorshuizen","year":"2004","unstructured":"Termorshuizen, F. Relative Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialysis Patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Journal of the American Society of Nephrology 15, 1061\u20131070 (2004).","journal-title":"Journal of the American Society of Nephrology"},{"key":"54572_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/ajkd.2001.25198","volume":"38","author":"D Shemin","year":"2001","unstructured":"Shemin, D., Bostom, A. G., Laliberty, P. & Dworkin, L. D. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 38, 85\u201390 (2001).","journal-title":"Am J Kidney Dis"},{"key":"54572_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.kint.2016.02.037","volume":"90","author":"AT Mathew","year":"2016","unstructured":"Mathew, A. T., Fishbane, S., Obi, Y. & Kalantar-Zadeh, K. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int 90, 262\u2013271 (2016).","journal-title":"Kidney Int"},{"key":"54572_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MAJ.0b013e3181cf7d5b","volume":"339","author":"ZZ Brener","year":"2010","unstructured":"Brener, Z. Z., Kotanko, P., Thijssen, S., Winchester, J. F. & Bergman, M. Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians. Am J Med Sci 339, 453\u2013456 (2010).","journal-title":"Am J Med Sci"},{"key":"54572_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/sj.ki.5000382","volume":"69","author":"AY Wang","year":"2006","unstructured":"Wang, A. Y. & Lai, K. N. The importance of residual renal function in dialysis patients. Kidney Int 69, 1726\u20131732 (2006).","journal-title":"Kidney Int"},{"key":"54572_CR7","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zeng, X., Fu, P. & Wu, H. M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev, CD009120 (2014).","DOI":"10.1002\/14651858.CD009120.pub2"},{"key":"54572_CR8","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1681\/ASN.2016060693","volume":"27","author":"AY Wang","year":"2016","unstructured":"Wang, A. Y. Preserving Residual Kidney Function in Hemodialysis Patients-Back in the Spotlight. J Am Soc Nephrol 27, 3504\u20133507 (2016).","journal-title":"J Am Soc Nephrol"},{"key":"54572_CR9","first-page":"341","volume":"5","author":"KW Group.","year":"2012","unstructured":"Group., K. W. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease: summary of recommendation statements. Kidney Int Suppl. 5, 341\u2013342 (2012).","journal-title":"Kidney Int Suppl."},{"key":"54572_CR10","first-page":"A3","volume":"45","author":"K\/DOQI","year":"2005","unstructured":"K\/DOQI. Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. American Journal of Kidney Diseases 45, A3\u2013A4 (2005).","journal-title":"American Journal of Kidney Diseases"},{"key":"54572_CR11","doi-asserted-by":"crossref","unstructured":"Weir, M. R., et al. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Am J Kidney Dis (2018).","DOI":"10.1053\/j.ajkd.2018.06.010"},{"key":"54572_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2215\/CJN.07831109","volume":"5","author":"DJ Tai","year":"2010","unstructured":"Tai, D. J. et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 5, 623\u2013630 (2010).","journal-title":"Clin J Am Soc Nephrol"},{"key":"54572_CR13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V113556","volume":"11","author":"M LOUISE","year":"2000","unstructured":"LOUISE, M. MOIST, e.a. Predictors of Loss of Residual Renal Function among New Dialysis Patients. J Am Soc Nephrol 11, 556\u2013564 (2000).","journal-title":"J Am Soc Nephrol"},{"key":"54572_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1744-9987.2012.01087.x","volume":"16","author":"Y Itoh","year":"2012","unstructured":"Itoh, Y. et al. Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients. Ther Apher Dial 16, 554\u2013559 (2012).","journal-title":"Ther Apher Dial"},{"key":"54572_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1053\/j.ajkd.2014.05.011","volume":"64","author":"KD Kjaergaard","year":"2014","unstructured":"Kjaergaard, K. D. et al. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis 64, 892\u2013901 (2014).","journal-title":"Am J Kidney Dis"},{"key":"54572_CR16","doi-asserted-by":"publisher","first-page":"184527","DOI":"10.5402\/2013\/184527","volume":"2013","author":"D Xydakis","year":"2013","unstructured":"Xydakis, D. et al. Residual renal function in hemodialysis patients: the role of Angiotensin-converting enzyme inhibitor in its preservation. ISRN Nephrol 2013, 184527 (2013).","journal-title":"ISRN Nephrol"},{"key":"54572_CR17","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/ndt\/17.10.1814","volume":"17","author":"LS Schiffl H","year":"2002","unstructured":"Schiffl H, L. S. & Fischer, R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 17, 1814\u20131818 (2002).","journal-title":"Nephrol Dial Transplant"},{"key":"54572_CR18","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","volume":"66","author":"National Kidney","year":"2015","unstructured":"National Kidney. F. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update. Am J Kidney Dis 66, 884\u2013930 (2015).","journal-title":"Am J Kidney Dis"},{"key":"54572_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000449029","volume":"2","author":"X Liu","year":"2017","unstructured":"Liu, X. & Dai, C. Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease. Kidney Dis (Basel) 2, 187\u2013196 (2017).","journal-title":"Kidney Dis (Basel)"},{"key":"54572_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.amjms.2015.12.021","volume":"351","author":"T Slomka","year":"2016","unstructured":"Slomka, T. et al. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease. Am J Med Sci 351, 309\u2013316 (2016).","journal-title":"Am J Med Sci"},{"key":"54572_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","volume":"18","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Ma, X., Zheng, J., Jia, J. & Yan, T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol 18, 206 (2017).","journal-title":"BMC Nephrol"},{"key":"54572_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.23876\/j.krcp.18.0115","volume":"38","author":"R Witoon","year":"2019","unstructured":"Witoon, R., Yongsiri, S., Buranaburidej, P. & Nanna, P. Efficacy of triple diuretic treatment in continuous ambulatory peritoneal dialysis patients: A randomized controlled trial. Kidney Res Clin Pract 38, 108\u2013115 (2019).","journal-title":"Kidney Res Clin Pract"},{"key":"54572_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/sdi.12557","volume":"30","author":"J Wong","year":"2017","unstructured":"Wong, J., Kaja Kamal, R. M., Vilar, E. & Farrington, K. Measuring Residual Renal Function in Hemodialysis Patients without Urine Collection. Semin Dial 30, 39\u201349 (2017).","journal-title":"Semin Dial"},{"key":"54572_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.kint.2015.10.011","volume":"89","author":"T Shafi","year":"2016","unstructured":"Shafi, T. et al. Estimating residual kidney function in dialysis patients without urine collection. Kidney Int 89, 1099\u20131110 (2016).","journal-title":"Kidney Int"},{"key":"54572_CR25","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.kint.2016.02.008","volume":"89","author":"A Davenport","year":"2016","unstructured":"Davenport, A. Measuring residual renal function in dialysis patients: can we dispense with 24-hour urine collections? Kidney Int 89, 978\u2013980 (2016).","journal-title":"Kidney Int"},{"key":"54572_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2215\/CJN.05520516","volume":"12","author":"MJ Lee","year":"2017","unstructured":"Lee, M. J. et al. Prognostic Value of Residual Urine Volume, GFR by 24-hour Urine Collection, and eGFR in Patients Receiving Dialysis. Clin J Am Soc Nephrol 12, 426\u2013434 (2017).","journal-title":"Clin J Am Soc Nephrol"},{"key":"54572_CR27","doi-asserted-by":"publisher","first-page":"e84257","DOI":"10.1371\/journal.pone.0084257","volume":"8","author":"JY Choi","year":"2013","unstructured":"Choi, J. Y. et al. Survival advantage of peritoneal dialysis relative to hemodialysis in the early period of incident dialysis patients: a nationwide prospective propensity-matched study in Korea. PLoS One 8, e84257 (2013).","journal-title":"PLoS One"},{"key":"54572_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ekir.2018.07.023","volume":"3","author":"KD Yoo","year":"2018","unstructured":"Yoo, K. D. et al. Effect of Renin-Angiotensin-Aldosterone System Blockade on Outcomes in Patients With ESRD: A Prospective Cohort Study in Korea. Kidney Int Rep 3, 1385\u20131393 (2018).","journal-title":"Kidney Int Rep"},{"key":"54572_CR29","doi-asserted-by":"publisher","first-page":"e1636","DOI":"10.1097\/MD.0000000000001636","volume":"94","author":"HJ Oh","year":"2015","unstructured":"Oh, H. J. et al. Which Biomarker is the Best for Predicting Mortality in Incident Peritoneal Dialysis Patients: NT-ProBNP, Cardiac TnT, or hsCRP?: A Prospective Observational Study. Medicine (Baltimore) 94, e1636 (2015).","journal-title":"Medicine (Baltimore)"},{"key":"54572_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40, 373\u2013383 (1987).","journal-title":"J Chronic Dis"},{"key":"54572_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/0735-1097(94)00371-V","volume":"25","author":"PM Okin","year":"1995","unstructured":"Okin, P. M., Roman, M. J., Devereux, R. B. & Kligfield, P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. Journal of the American College of Cardiology 25, 417\u2013423 (1995).","journal-title":"Journal of the American College of Cardiology"},{"key":"54572_CR32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang, R. M. et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18, 1440\u20131463 (2005).","journal-title":"J Am Soc Echocardiogr"},{"key":"54572_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2005.01.019","volume":"45","author":"K\/DOQI","year":"2005","unstructured":"K\/DOQI. Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. American Journal of Kidney Diseases 45, 16\u2013153 (2005).","journal-title":"American Journal of Kidney Diseases"},{"key":"54572_CR34","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","volume":"16","author":"C Avitalm","year":"1997","unstructured":"Avitalm, C., Nan, M. L. & Peter, S. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statist. Med. 16, 2349\u20132380 (1997).","journal-title":"Statist. Med."},{"key":"54572_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1099800404267682","volume":"6","author":"C Krueger","year":"2004","unstructured":"Krueger, C. & Tian, L. A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points. Biol Res Nurs 6, 151\u2013157 (2004).","journal-title":"Biol Res Nurs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54572-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:50:53Z","timestamp":1671295853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54572-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54572"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54572-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18103"}}